Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne
Wave Life Sciences Ltd. announced its decision to discontinue development of suvodirsen for patients with Duchenne who have mutations amenable to exon 51 skipping, based on its interim analysis of the Phase 1 open-label extension…Learn More